Eating Disorder Risk and Screening in Patients Using GLP-1 Receptor Agonists Compared to Weight Loss Surgery

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for weight management.

• There is limited knowledge on the effects of GLP-1RAs on individuals with eating disorders (EDs).
• The potential for GLP-1RAs to promote, mask, or exacerbate ED psychopathology is not well understood.
• Current empirical data directly linking GLP-1RAs and ED risk is lacking.
• Insights from metabolic and bariatric surgery (MBS) may inform understanding of GLP-1RAs in the context of EDs.
• This summary aims to highlight critical knowledge gaps and guide interim decision-making for various stakeholders.

Simplified